Aya terobosan panganyarna dina kanker paru sél non-leutik. Hiji jenis imunisasi anu tiasa ngubaran kanker paru-paru sél sanés-sakedik (NSCLC) parantos ngalaman persetujuan klinis tahap 3 sareng ngagaduhan pangaruh terapi hébat kana panyakit paru-paru sél alit. Ayeuna tiasa diaksés di sababaraha nagara.
As an anti-idiotype monoclonal antibody, the vaccine enables lung cancer patients to respond strongly to specific glycosylated gangliosides (NeuGcGM3) in cancer cells. Compared with the best supportive care, lung vaksin kanker tiasa ningkatkeun tingkat kasalametan pasien kalayan tahap kambuh sareng maju (tahap IIIB / IV) NSCLC.
Rather than numerous warm blooded creatures, including gorillas, we can’t recognize the nearness of NeuGcGM3 gangliosides in typical human tissues and liquids. Be that as it may, NeuGcGM3 gangliosides are profoundly communicated in certain human malignant growth cells. In non-little cell lung malignancy tests, gangliosides were identified in over 90% of non-little cell lung tumors. Thusly, NeuGcGM3 ganglioside can be utilized as a ground-breaking objective for lung malignant growth antibodies.
Saatos kerangka anu teu kahontal ngahasilkeun antibodi eksplisit ngalawan an antigén, éta tiasa nyiptakeun antibodi ngalawan keun keun antigen utama, anu tiasa ngendalikeun kerangka tahan ti jero. Dina hudangna diimunisasi ngalawan pertumbuhan ganas paru-paru ieu imunisasi, it can advance the generation of antibodies against this antigen, assigned Ab1. These Ab1 antibodies are fit for delivering a progression of hostile to idiotypic antibodies, assigned Ab2. The idiotypes of these exceptional antibodies are fused into the antigen-restricting site of Ab1, with the goal that these extraordinary antibodies produce a particular resistant reaction to regular antigens. Hence, vaccination with Ab2 immunizer can advance the creation of Ab3 (hostile to against idiotype neutralizer), and this Ab3 counter acting agent can perceive the first antigen perceived by Ab1. Some Ab2 antibodies of this sort invigorate the safe framework to actuate defensive resistance against tumor antigén.
Éta parantos sacara klinis nunjukkeun yén panyakit paru-paru imunisasi pisan tahan sareng langkung saé dijalankeunnana. Seueur gejala dasar kajadian ngan ukur sacara lokal (situs infus) sareng umumna lembut sareng panjangna pondok. Henteu paduli naha antibodi dirumuskeun ka pasién saatos kaayaan na parantos hancur, daya tahan umumna parantos ningkat.
Ayeuna, imunisasi pertumbuhan ganas paru-paru ieu henteu dipromosikeun di India.
